At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 250 enrolled
Drug / intervention
Zoster Vaccine Livebiological
Likely dose
Zoster Vaccine Live 0.65 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in India
In Brief
A Phase 3 clinical trial evaluating Zoster Vaccine Live for Herpes Zoster and Shingles. Completed, enrolled 250 participants.
Detailed Summary
This study will determine if ZOSTAVAX™ is safe, tolerable, and immunogenic in healthy adults in India.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster, Shingles
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartOct 2012
Primary CompletionApr 2013
TodayJul 2026
First PostedFeb 7, 2012
Enrollment StartOct 31, 2012
Primary CompletionApr 9, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.4 years ago
Interventions
Zoster Vaccine Livebiological
One approximately 0.65 mL injection subcutaneously on Day 1